大型3型/4型胃癌に対する術前S-1＋CDDP＋DTX併用療法による第II相試験（OGSG 1402）：5年長期成績

Tumor Response Predicts Survival Time of Ramucirumab Plus Irinotecan in Advanced Gastric Cancer: An Exploratory Analysis of the Phase III RINDBeRG Trial

高度リンパ節転移を伴う進行胃癌に対する周術期Capecitabine＋Oxaliplatin (CapeOx)療法の第II相試験(OGSG1701)の最終生存解析

A Multicenter Phase 2 Trial of Ramucirumab Plus Irinotecan in Patients with Early Relapsed Gastric Cancer During or After Adjuvant Docetaxel Plus S-1 Therapy: RAMIEL Trial (OGSG1901)

Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for large type 3 or type 4 gastric cancer Final outcomes (OGSG1902)

胃癌へのICI導入後におけるConversion手術の実際 -高齢者に着目したリアルワールドデータ(OGSG2301)-

Conversion Surgery in Advanced Gastric Cancer Patients Aged over 80 : Results from a Multi-Institutional Retrospective Study (OGSG2301)

進行胃癌に対する周術期capecitabine＋oxaliplatin(CapeOx)療法の術前化学療法としての有用性（OGSG1601、1701試験より）

Prognostic Implications of Neutropenia in Advanced Gastric Cancer: An Exploratory Analysis of the RINDBeRG Trial

Predictive Value of Nivolumab-Free Interval in Ramucirumab Plus Irinotecan Therapy: An Exploratory Analysis of the RINDBeRG Trial